EGFR

[Scientific Reports] Investigators established a model of CSCs that was originally developed from mouse induced pluripotent stem cells (miPSCs) by proposing miPSCs to the conditioned medium of cancer derived cells, which was a mimic of carcinoma microenvironment.

[Cell Death & Disease] Researchers identified neurokinin-1 as a significantly upregulated GPCR in the transcriptome and tissue array of human lung cancer samples, associated with advanced clinical stages and poor prognosis.

[International Journal of Biological Sciences] Researchers found that decreased expression of ITGB4 was negatively correlated with the level of MUC5AC in childhood airway epithelial cells following respiratory syncytial virus (RSV) infection.

[Genprex, Inc.] Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.

[npj Precision Oncology] Complementary functional analyses of polyclonal EGFR-mutant cell pools showed a dose-dependent enrichment of BRAFV600E and a loss of EGFR inhibitor susceptibility.

[Cullinan Oncology, Inc.] Cullinan Oncology, Inc. reported updated data from the Company’s ongoing Phase I/IIa trial of CLN-081 in non-small cell lung cancer patients whose tumors harbor epidermal growth factor receptor exon 20 insertion mutations that have progressed on or after prior therapy.